|
|||||||||||||||
|
|||||||||||||||
LSI names external advisory boardThe Life Sciences Institute (LSI) has named a 15-member external advisory board of leading figures from science and industry to guide its operations. The board includes distinguished academic researchers and leaders of health science companies, who will meet annually to review and guide the institute's scientific and financial operations.
Chairing the group will be Ronnie Cresswell, who formerly was a senior vice president of Warner Lambert Co. and the chairman of Parke-Davis Pharmaceutical Research in Ann Arbor. "The Life Sciences Institute is a bold step forward by the University of Michigan," Cresswell says. "It's exciting for me to help lead this effort to blaze a new trail in biomedical research. We've assembled a really stellar group of advisors, and I'm looking forward to working with them on this vital project." Alan Saltiel, director of LSI, also is looking forward to working with the advisory board. "We've recruited a spectacular group of advisors. I am excited that each has agreed to lend their expertise to our venture. They will keep us focused on the forefront of science and insure that we remain connected to the broader community in both the public and private sector."
External Advisory Board • Ronnie Cresswell, chair • Dr. Keith Black*, director, Maxine Dunitz Neurosurgical Institute and Division of Neurosurgery, Cedars Sinai Medical Center, Los Angeles • Sir William Castell, chief executive, Amersham plc, Buckinghamshire, U.K., who was knighted by Queen Elizabeth II in 2000 for his services to the life sciences industry • Dr. Peter B. Corr, senior vice president, Science and Technology, Pfizer Inc. Global Research and Development, New London, Conn. • Dr. Pedro Cuatrecasas, retired president, Parke Davis/Warner Lambert Pharmaceutical Research Division. A former National Institutes of Health researcher and currently professor of pharmacology and medicine at the University of California, San Diego • Jack E. Dixon, dean for scientific affairs, University of California, San Diego • Jennifer A. Doudna, Howard Hughes Medical Institute investigator and professor of molecular and cell biology, University of California, Berkeley • Dr. Richard P. Lifton,Howard Hughes Medical Institute investigator and Sterling Professor of Genetics and Internal Medicine, Yale University School of Medicine • Harvey F. Lodish, Whitehead Institute member, professor of biology and bioengineering, Massachusetts Institute of Technology • Paul M. Meister*, vice chairman, Fisher Scientific International Inc., Hampton, N.H. • Randy W. Schekman, Howard Hughes Medical Institute investigator, professor of molecular and cell biology, University of California, Berkeley • Christopher T. Walsh, Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston • B. Joseph White*, managing director, Fred Alger Management Co., New York. Formerly U-M professor of Business Administration, dean of the Business School and interim president of the University • Dr. Tadataka Yamada, chairman, research and development, GlaxoSmithKline, King of Prussia, Penn.
More stories
|
|||||||||||||||
|
|||||||||||||||